DermTech, Inc. (DMTKQ)

OTCMKTS · Delayed Price · Currency is USD
0.0000
0.00 (0.00%)
Mar 27, 2025, 4:00 PM EST
-100.00%
Market Cap 35.00
Revenue (ttm) 15.66M
Net Income (ttm) -89.63M
Shares Out 35.26M
EPS (ttm) -2.67
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 274,269
Average Volume 902
Open 0.0001
Previous Close n/a
Day's Range n/a
52-Week Range n/a
Beta 1.41
RSI 44.45
Earnings Date Feb 28, 2025

About DermTech

DermTech, Inc., a molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it ... [Read more]

Industry Medical - Diagnostics & Research
Sector Healthcare
CEO Bret Christensen
Employees 208
Stock Exchange OTCMKTS
Ticker Symbol DMTKQ
Full Company Profile

Financial Performance

In 2023, DermTech's revenue was $15.30 million, an increase of 5.36% compared to the previous year's $14.52 million. Losses were -$100.89 million, -13.54% less than in 2022.

Financial Statements

News

DermTech Completes Transaction for Asset Sale; Operations Continue Under New Ownership and Management

SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (OTC: DMTKQ) (DermTech or the Company) a leader in precision dermatology offering non-invasive skin genomics solutions, today announced that it has closed it...

7 months ago - Business Wire